HomeInsightsStock Comparison

Venus Remedies Ltd vs Vivanza Biosciences Ltd Stock Comparison

Venus Remedies Ltd vs Vivanza Biosciences Ltd Stock Comparison

Last Updated on: Jul 22, 2025

Key Highlights

  • The Latest Trading Price of Venus Remedies Ltd is ₹ 529.35 as of 22 Jul 11:52.
  • The P/E Ratio of Venus Remedies Ltd changed from 5.5 on March 2021 to 15.3 on March 2024 . This represents a CAGR of 29.15% over 4 yearsThe P/E Ratio of Vivanza Biosciences Ltd changed from 687.4 on March 2021 to 48.5 on March 2024 . This represents a CAGR of -48.46% over 4 years.
  • The Market Cap of Venus Remedies Ltd changed from ₹ 27.77 crore on March 2020 to ₹ 436.3 crore on March 2024 . This represents a CAGR of 73.48% over 5 yearsThe Market Cap of Vivanza Biosciences Ltd changed from ₹ 52.24 crore on March 2021 to ₹ 27.16 crore on March 2024 . This represents a CAGR of -15.09% over 4 years.
  • The revenue of Venus Remedies Ltd for the Mar '25 is ₹ 201.73 crore as compare to the Dec '24 revenue of ₹ 188.8 crore. This represent the growth of 6.85% The revenue of Vivanza Biosciences Ltd for the Mar '25 is ₹ 0.53 crore as compare to the Dec '24 revenue of ₹ 1.51 crore. This represent the decline of -64.9%.
  • The ebitda of Venus Remedies Ltd for the Mar '25 is ₹ 35.76 crore as compare to the Dec '24 ebitda of ₹ 30.3 crore. This represent the growth of 18.02% The ebitda of Vivanza Biosciences Ltd for the Mar '25 is ₹ -0.91 crore as compare to the Dec '24 ebitda of ₹ 0.13 crore. This represent the decline of -800%.
  • The net profit of Venus Remedies Ltd changed from ₹ 1.18 crore to ₹ 21 crore over 8 quarters. This represents a CAGR of 321.86% The net profit of Vivanza Biosciences Ltd changed from ₹ 0.49 crore to ₹ -1 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Venus Remedies Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vivanza Biosciences Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Venus Remedies Ltd

  • Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited.
  • The Company was promoted and managed by Chaudhary & Family.
  • The Company is one of the handful player in pharmaceutical sector to launch injectables globally.
  • It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India).
  • In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana.

About Vivanza Biosciences Ltd

  • Vivanza Biosciences Limited(Previously known Ivee Injectaa Limited) was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992.
  • Due to recessionary trends which lead to difficult business conditions in the year 1999-2000, the parenteral industry suffered a setback.
  • As a result of this, the name of the Company was changed from Ivee Injectaa Limited to Vivanza Biosciences Limited in 2015. The Company is focused in commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines.
  • It is presently engaged in the business of Pharmaceutical Products and Pharma Products. Head quartered in Gujarat, India, Company came into existence in April 2016 to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system.

Venus Remedies Ltd News Hub

News

Venus Remedies to hold AGM

Venus Remedies announced that the 36th Annual General Meeting(AGM) of the company will be ...

Read more

10 Jul 2025 09:50

News

Venus Remedies to conduct board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 8 July 2025...

Read more

27 Jun 2025 16:28

News

Venus Remedies spurts after Q4 PAT climbs 100% YoY to Rs 21 cr

However, revenue from operations decreased marginally to Rs 194.97 crore in Q4 FY25, as ag...

Read more

27 May 2025 11:37

News

Venus Remedies to hold board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2025...

Read more

17 May 2025 16:57

News

Venus Remedies jumps as investigational drug secures QIDP tag from USFDA

The drug is intended for the treatment of bloodstream infections caused by polymyxin B (PM...

Read more

17 Apr 2025 10:23

News

Venus Remedies gains on strategic MET-X partnership

MET-X, a metallo-beta-lactamase (MBL) inhibitor, targets drug-resistant Gram-negative bact...

Read more

25 Feb 2025 11:26

Vivanza Biosciences Ltd News Hub

News

Vivanza Biosciences to table results

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 12 May...

Read more

08 May 2025 11:19

News

Vivanza Biosciences announces board meeting date

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 12 May...

Read more

07 May 2025 11:35

News

Vivanza Biosciences to discuss results

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 31 Jan...

Read more

25 Jan 2025 10:18

News

Vivanza Biosciences to declare Quarterly Result

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 17 Oct...

Read more

11 Oct 2024 10:17

News

Vivanza Biosciences to announce Quarterly Result

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 8 Augu...

Read more

03 Aug 2024 17:02

News

Vivanza Biosciences to convene AGM

Vivanza Biosciences announced that the 42nd Annual General Meeting (AGM) of the company wi...

Read more

08 Jul 2024 10:49

SWOT Analysis Of Vivanza Biosciences Ltd

Strength

2

S

Weakness

3

W

Opportunity

1

O

Threats

0

T

SWOT Analysis Of Venus Remedies Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Vivanza Biosciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Venus Remedies Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Venus Remedies Ltd and Vivanza Biosciences Ltd

Which company has a larger market capitalization, Venus Remedies Ltd or Vivanza Biosciences Ltd?

Market cap of Venus Remedies Ltd is 722 Cr while Market cap of Vivanza Biosciences Ltd is 8 Cr

What are the key factors driving the stock performance of Venus Remedies Ltd and Vivanza Biosciences Ltd?

The stock performance of Venus Remedies Ltd and Vivanza Biosciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Venus Remedies Ltd and Vivanza Biosciences Ltd?

As of July 22, 2025, the Venus Remedies Ltd stock price is INR ₹540.15. On the other hand, Vivanza Biosciences Ltd stock price is INR ₹2.09.

How do dividend payouts of Venus Remedies Ltd and Vivanza Biosciences Ltd compare?

To compare the dividend payouts of Venus Remedies Ltd and Vivanza Biosciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions